Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;128(2):161-164.
doi: 10.1038/s41416-022-02107-8. Epub 2023 Jan 4.

The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care

Maria Antonietta Cerone #  1 , Tara C Mills #  2 , Rowena Sharpe  3 , David McBride  4 , Moira MacDonald  5 , Suzanne MacMahon  6 , Hood Mugalaasi  6 , Pauline Rehal  7 , Alessandro Rettino  7 , Helen Roberts  5 , Mark Ross  4 , Donald Edward White  1 , John Peden  8 , Janette Rawlinson  9 , Steffan N Ho  10 , Simon Hollingsworth  11 , Sanjay Popat  12 , Gary Middleton  13 , Peter Johnson  14 , Charles Swanton  15 ; SMP2 consortium
Collaborators, Affiliations

The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care

Maria Antonietta Cerone et al. Br J Cancer. 2023 Jan.

Erratum in

Abstract

Genomic screening is routinely used to guide the treatment of cancer patients in many countries. However, several multi-layered factors make this effort difficult to deliver within a clinically relevant timeframe. Here we share the learnings from the CRUK-funded Stratified Medicine Programme for advanced NSCLC patients, which could be useful to better plan future studies.

PubMed Disclaimer

Conflict of interest statement

SMM has received compensation as a member of the scientific advisory board of AstraZeneca. GM received honoraria for advisory boards/speaker engagements from BMS, MSD, AZ, Roche, D2G, Servier and Merck Serono. Prof Swanton acknowledges grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana, Boehringer-Ingelheim, Invitae (previously Archer Dx Inc)—collaboration in minimal residual disease sequencing technologies, and Ono Pharmaceutical, and is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s Scientific Advisory Board. He receives consultant fees from Achilles Therapeutics (also SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre—Shanghai, Metabomed (until July 2022) and the Sarah Cannon Research Institute C.S has received honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina and Roche-Ventana; had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics (Patents: C.S. holds patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892)). SP reported receiving consultancy honoraria and research funding from Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Guardant Health, Janssen, Lilly, MSD, Roche, Seattle Genetics, Takeda, Turning Point Therapeutics; consultancy honoraria from Bayer, BeiGene, EQRx, Merck KGaA, Novartis, Pfizer and Sanofi; he is an advisor for ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation; part of the board of directors of Mesothelioma Applied Research Foundation and leadership for BTOG Steering Committee, ETOP Foundation Council. MR and DMB are employees of Illumina, a public company that develops and markets systems for genetic analysis. SNH is an employee of Pfizer. SH is a full-time employee of AstraZeneca and holds stock in AstraZeneca and Roche/Genentech. JP was an employee of Illumina during the programme. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. SMP2 at a glance.
a SMP2 consort graph showing absolute numbers and percentage of tested patients. Patients not recruited to NLMT included patients on standard of care (SOC) treatment or dead at the time of closure, patients who could not be recruited due to poor performance status (PS) and patients who stopped treatment due to toxicity. b Comparison of NGS success rates for the 3 panels. The percentages of samples where the indicated fraction of genes was successfully sequenced are shown. All differences between panels are significant (p < 0.01). c Types of gene aberrations detected. The fractions of genes successfully sequenced in which the indicated aberration was detected over all genes passed are shown. **p < 0.01, Fisher’s exact test. d SCNA detection by panel. The fractions of patients where an amplification or deletion in the indicated genes was detected over the number of patients where the gene was successfully sequenced are shown. Only genes for which at least 50 SCNA events have been observed in the SMP2 cohort are included. ● = **; **p < 0.01, Fisher’s exact test.
See this image and copyright information in PMC

References

    1. Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, et al. Challenges in molecular testing in non-small-cell lung cancer patients with advanced diseases. Lancet. 2016;388:1002–112016. doi: 10.1016/S0140-6736(16)31340-X. - DOI - PubMed
    1. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, et al. The National Lung Matrix Trial of personalised therapy in lung cancer. Nature. 2020;583:807–12. doi: 10.1038/s41586-020-2481-8. - DOI - PMC - PubMed
    1. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, et al. The Molecular Analysis for Therapy Choice (NCI-MATCH) trial: lessons for genomic trial design. J Natl Cancer Inst. 2020;112:1021–9. doi: 10.1093/jnci/djz245. - DOI - PMC - PubMed
    1. Murciano-Goroff YR, Drilon A, Stadler ZK. The NCI-MATCH: a national, collaborative precision oncology trial for diverse tumour histologies. Cancer Cell. 2021;39:22–24. doi: 10.1016/j.ccell.2020.12.021. - DOI - PMC - PubMed
    1. Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwarts LH, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020;21:1589–602. - PMC - PubMed

Publication types

MeSH terms